Acumen Pharmaceuticals In... (ABOS)
Acumen Pharmaceuticals Inc. (ABOS) Stock Price, Analysis & Data
| Bid | 1.99 |
| Market Cap | 198.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -105.04M |
| Beta | 0.33 |
| EPS (ttm) | -1.69 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.91 |
| P/B (ttm) | 3.46 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 11, 2026 |
| Ask | 3.41 |
| Volume | 304,144 |
| Avg. Volume (20D) | 460,596 |
| Open | 2.66 |
| Previous Close | 2.66 |
| Day's Range | 2.65 - 2.79 |
| 52-Week Range | 1.21 - 3.60 |
| Analyst | Strong Buy |
| Price Target | 8 (191.97%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcu...
Financial Performance
In 2025, Acumen Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -121.33M, an increase of 18.57%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for ABOS stock is "Strong Buy". The 12-month stock price forecast is 8, which is upside of 191.97% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
